Danaher Corporation $DHR Stock Position Increased by Eurizon Capital SGR S.p.A.

Eurizon Capital SGR S.p.A. raised its stake in shares of Danaher Corporation (NYSE:DHR) by 16.8% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 284,412 shares of the conglomerate’s stock after purchasing an additional 41,003 shares during the period. Eurizon Capital SGR S.p.A.’s holdings in Danaher were worth $63,120,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently made changes to their positions in the company. Prime Capital Investment Advisors LLC lifted its position in shares of Danaher by 0.5% in the third quarter. Prime Capital Investment Advisors LLC now owns 9,203 shares of the conglomerate’s stock worth $2,039,000 after buying an additional 45 shares in the last quarter. Essential Investment Partners LLC increased its stake in Danaher by 34.6% in the 3rd quarter. Essential Investment Partners LLC now owns 175 shares of the conglomerate’s stock worth $39,000 after acquiring an additional 45 shares during the last quarter. Montis Financial LLC increased its stake in Danaher by 2.3% in the 3rd quarter. Montis Financial LLC now owns 2,020 shares of the conglomerate’s stock worth $448,000 after acquiring an additional 46 shares during the last quarter. Covestor Ltd raised its holdings in shares of Danaher by 28.3% during the 3rd quarter. Covestor Ltd now owns 213 shares of the conglomerate’s stock worth $47,000 after acquiring an additional 47 shares in the last quarter. Finally, Veery Capital LLC raised its holdings in shares of Danaher by 3.1% during the 3rd quarter. Veery Capital LLC now owns 1,581 shares of the conglomerate’s stock worth $350,000 after acquiring an additional 48 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Stock Performance

Danaher stock opened at $232.08 on Friday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.29 and a current ratio of 1.63. The company has a market capitalization of $163.28 billion, a PE ratio of 37.98, a P/E/G ratio of 2.95 and a beta of 0.76. The company has a 50 day moving average price of $222.11 and a 200-day moving average price of $201.53. Danaher Corporation has a fifty-two week low of $160.93 and a fifty-two week high of $242.80.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Wednesday, October 21st. The conglomerate reported $2.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.92 by $0.19. The company had revenue of $6.55 billion for the quarter, compared to analysts’ expectations of $6.56 billion. Danaher had a return on equity of 11.17% and a net margin of 16.91%. Danaher’s revenue was up 8.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.89 earnings per share. As a group, equities analysts forecast that Danaher Corporation will post 8.59 earnings per share for the current year.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th were given a dividend of $0.40 per share. The ex-dividend date of this dividend was Wednesday, September 30th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.7%. Danaher’s dividend payout ratio is presently 26.19%.

Insiders Place Their Bets

In related news, EVP Gregory M. Milosevich sold 2,100 shares of the business’s stock in a transaction that occurred on Monday, November 9th. The shares were sold at an average price of $230.62, for a total value of $484,302.00. Following the completion of the transaction, the executive vice president owned 22,367 shares of the company’s stock, valued at $5,158,277.54. The trade was a 8.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CAO Christopher Bouda sold 7,598 shares of the business’s stock in a transaction on Wednesday, October 28th. The stock was sold at an average price of $234.56, for a total value of $1,782,186.88. Following the completion of the transaction, the chief accounting officer directly owned 9,107 shares of the company’s stock, valued at approximately $2,136,137.92. The trade was a 45.48% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 10.80% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

DHR has been the subject of a number of recent research reports. Guggenheim lifted their price objective on shares of Danaher from $200.00 to $250.00 and gave the stock a “buy” rating in a research note on Thursday, October 1st. Stifel Nicolaus upped their price objective on Danaher from $220.00 to $260.00 and gave the company a “buy” rating in a research report on Thursday, October 22nd. Deutsche Bank reiterated a “buy” rating and set a $240.00 target price on shares of Danaher in a research report on Wednesday, July 22nd. Barclays boosted their target price on shares of Danaher from $255.00 to $260.00 and gave the company an “overweight” rating in a research note on Thursday, October 22nd. Finally, Wells Fargo & Company cut their price target on shares of Danaher from $212.00 to $195.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 22nd. Eighteen analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $242.91.

About Danaher

Danaher is a global science and technology company that develops and supplies products and services for biotechnology, life sciences, and diagnostics markets. Its offerings include instruments, reagents, consumables, software, and services used in research, drug development and manufacturing, and clinical testing. The company’s businesses include well-known brands such as Cytiva and Pall in bioprocessing and filtration, Beckman Coulter in laboratory and clinical diagnostics, Cepheid in molecular diagnostics, and Leica Microsystems in microscopy.